X-chromosome Inactivation, Epigenetics and the Transcriptome
|ClinicalTrials.gov Identifier: NCT01678261|
Recruitment Status : Completed
First Posted : September 3, 2012
Last Update Posted : May 24, 2016
|First Submitted Date||August 30, 2012|
|First Posted Date||September 3, 2012|
|Last Update Posted Date||May 24, 2016|
|Start Date||September 2012|
|Primary Completion Date||October 2015 (Final data collection date for primary outcome measure)|
|Current Primary Outcome Measures
|Original Primary Outcome Measures||Same as current|
|Change History||Complete list of historical versions of study NCT01678261 on ClinicalTrials.gov Archive Site|
|Current Secondary Outcome Measures||Not Provided|
|Original Secondary Outcome Measures||Not Provided|
|Current Other Outcome Measures||Not Provided|
|Original Other Outcome Measures||Not Provided|
|Brief Title||X-chromosome Inactivation, Epigenetics and the Transcriptome|
|Official Title||X-chromosome Inactivation, Epigenetics and the Transcriptome|
The human genetic material consists of 46 chromosomes of which two are sex chromosomes. The sex-chromosome from the mother is the X and from the father the Y-chromosome. Hence a male consist of one Y and one X chromosome and a female of 2 X-chromosomes. Alterations in the number of sex-chromosomes and in particular the X-chromosome is fundamental to the development of numerous syndromes such as Turner syndrome (45,X), Klinefelter syndrome (47,XXY), triple X syndrome (47,XXX) and double Y syndrome (47,XYY). Despite the obvious association between the X-chromosome and disease only one gene has been shown to be of significance, namely the short stature homeobox gene (SHOX). Turner syndrome is the most well characterized and the typical diseases affecting the syndrome are:
In healthy women with to normal X-chromosomes, the one of the X-chromosomes is switched off (silenced). The X-chromosome which is silenced varies from cell to cell. The silencing is controlled by a part of the X-chromosome designated XIC (X-inactivation center). The inactivation/silencing of the X-chromosome is initiated by a gene named Xist-gene (the X inactivation specific transcript).This gene encodes specific structures so called lincRNAs (long intervening specific transcripts) which are very similar to our genetic material (DNA) but which is not coding for proteins. The final result is that women are X-chromosome mosaics with one X-chromosome from the mother and the other X from the father. However, numerous genes on the X-chromosome escape this silencing process by an unknown mechanism. Approximately two third of the genes are silenced, 15 % avoid silencing and 20 percent are silenced or escape depending on the tissue of origin.
The aforementioned long non-protein-coding parts of our genetic material (LincRNAs) are abundant and produced in large quantities but their wole as respect to health and disease need further clarification. Studies indicate that these LincRNAs interact with the protein coding part of our genetic material modifying which genes are translated into proteins and which are not. During this re-modelling there is left foot prints on the genetic material which can indicate if it is a modification that results in silencing or translation of the gene. It is possible to map these foot prints along the entire X-chromosome using molecular techniques like ChIP (Chromatin immunoprecipitation) and ChIP-seq (deep sequencing).
The understanding achieved so far as to the interplay between our genetic material and disease has arisen from genetic syndromes which as the X-chromosome syndromes are relatively frequent and show clear manifestations of disease giving the researcher a possibility to identify genetic material linked to the disease. Turner and Klinefelter syndrome are, as the remaining sex chromosome syndromes, excellent human disease models and can as such help to elaborate on processes contributing to the development of diseases like diabetes, hypothyroidism, main artery dilation and ischemic heart disease.
The purpose of the study is to:
6. Determine if certain genes escape X-chromosome silencing and to establish if this is associated with the parent of origin.
The X chromosome is a cornerstone to the pathogenesis of a number of syndromes, whereof some are Turner syndrome (45,X), Klinefelter syndrome (47,XXY), triple X syndrome (47,XXX) and double Y syndrome (47,XYY). Despite this importance to clinical disease, only one gene on the X chromosome has so far been implicated in the wide spectra of phenotypic traits seen in these and other X-related syndromes. The one known gene is the SHOX (the short stature homeobox) gene and encodes a transcription factor that has brain natriuretic peptide (BNP) and fibroblast growth factor receptor gene (FGFR3) as transcriptional targets. It is located at the pseudoautosomal region of the X and Y chromosomes. This gene has been shown to be involved in short stature in Turner syndrome, Leri-Weill syndrome and idiopathic short stature. It also causes the increased stature in Klinefelter syndrome, triple X syndrome and XYY syndrome.
A number of traits and diseases are seen frequently in X-chromosomal syndromes that cannot be explained by this SHOX gene. The best characterized of these syndromes is Turner syndrome, where these phenotype traits can be divided into:
LincRNAs are pervasively transcribed in the genome, although their role in health and disease is poorly understood. Studies of dosage compensation, imprinting and homeotic gene expression suggest that lincRNAs function at the interface between DNA and chromatin remodeling with further involvement in reprogramming of chromatin to promote cancer metastasis. To date a range of different interactions have been hypothesized for lincRNAs in transcriptional regulation, and they may function both as intact interacting molecules as well as Dicer processed molecules that are chopped into small interfering RNAs that degrade other RNAs.
Chromatin remodeling can be analyzed by the marks left by histones on the DNA strand, which can be of either permissive or repressive nature, depending on the acetylation or methylation taking place of the histones. As an example, trimethylation of lysine 4 on histone H3 (H3K4me3) is enriched at transcriptionally active gene promoters, whereas trimethylation of H3K9 (H3Kme3) and H3K27 (H3K27me3) are present at gene promoters that are transcriptionally repressed. By use of chromatin immunoprecipitation coupled with deep sequencing (chIPseq) one can obtain these marks along the whole X chromosome in one assay.
The epigenetic alterations of histone modifications can be studied by a new methodology, enabling the use of relatively old pathological specimens. This opens new prospects for expansion of our knowledge of the role of the X-chromosomal permission and inactivation to different diseases, where X-chromosomal syndromes may serve as the initial model to understand such processes that are highly likely to be important to diseases (e.g. diabetes and hypothyroidism) beyond these syndromes. As another example, congenital malformations of the heart are frequent in Turner syndrome and often lead to early aortic dilatation and dissection. In these patients and in controls, we collect paraffin- embedded blocks of tissue from the aortic wall, which can now be assessed using this frontline methodology with a potential to identify novel marks on Turner patients DNA compared to the DNA of non-Turner patients.
Imprinting is another important aspect of sex chromosome action. Imprinting refers to the process where a gene (or more genes) may be imprinted depending on parental origin. Put another way, a gene can be "turned on or off" depending on its maternal of paternal origin. Furthermore, mouse studies show that clusters of genes on the X chromosome are imprinted and are independent of X chromosome inactivation.
The importance of the biological inheritance is apparent for the major cardiovascular morbidities affecting the population, where a hereditary trait clearly prevails in certain families. Despite a promise for targeting the prevention and treatment of cardiovascular morbidity, the specific parts of the genome that potentially trigger the pathologies largely remain to be defined, and could bring important knowledge of the pathophysiology.
The major body of knowledge on the implications of genome aberrations originates from diseases with obvious and severe manifestations resulting from clear modes of transmission that allow identification of the causative regions of the genome. Such genetic disorders hold the potential for understanding the role of a specific locus of the genome, if this can be identified, as large chromosomal regions often are involved. In the case of the X- chromosomal phenotypes we expect the causative agent to be on the X chromosome, and will use various novel technologies to identify this agent.
Currently, our limited knowledge of the importance of the X-chromosome to cardiovascular pathology comes from single-gene disorders, and more non-specific gender differences in addition to the sex chromosomal anomalies. In contrast, no single-gene disorder on the Y- chromosome has been established to be related to cardiovascular morbidity.
Appropriate human models for improved understanding of the role played by the sex chromosomes are available. Here, deviations from normality not only occur at a reasonable prevalence but also associate with readily identifiable phenotypes and adverse prognosis. Turner and Klinefelter syndromes constitute such models; females with a reduction in X- chromosomal material and males with an increase in X-chromosomal material, respectively. These anomalies of the sex-chromosomes associate with excess morbidity and mortality from both congenital and acquired cardiovascular as well as diabetes, ovarian insufficiency and other diseases.
The cardiovascular phenotypes and the expression and activation of genes are investigated in healthy females and males with a comparison between Turner and Klinefelter syndromes in a cross-sectional descriptive design. These studies have already been performed and a precise characterization is established. The hypothesis is that the significance of the X-chromosome will manifest as altered levels of expression and activation in association with different cardiovascular phenotypes. Secondarily, basic analogous knowledge is provided of the Y-chromosome. The project is expected to generate further hypotheses on the role played by the genome to morbidity in both the population having a normal karyotype as well as in abnormal karyotypes.
In this project we will provide a unique combination of front line molecular technologies and well defined patient cohorts. The hypotheses we will test are the following:
Expected findings. We expect to be able to define the epigenetic changes at the X-chromosomes at a single base resolution, thus identifying CpG methylation at the DNA strands as well as permissive and repressive histone marks in histones.
We expect to identify the transcriptome both regarding mRNA and non-coding RNAs (long as well as microRNAs) for RNAs generated from the X-chromosome.
We expect to be able to provide an Atlas of the epigenetic events specific for Turner syndromes and the effects of these on the transcriptome.
Using bioinformatic methods this will hopefully lead to identification of novel dysregulated molecules that may explain various properties of these patients. These molecules will then be subject to validation in separate patient cohorts using PCR or IHC technology.
In diseased tissue we will study the tissue specific alterations of the epigenome and transcriptome of the X chromosomes and compare this to normal tissues from the control samples. We hope this will lead to identification of the drivers of the disease process and a pathophysiological understanding of the disease process.
|Study Design||Observational Model: Cohort
Time Perspective: Cross-Sectional
|Target Follow-Up Duration||Not Provided|
|Biospecimen||Retention: Samples With DNA
|Sampling Method||Non-Probability Sample|
|Study Population||Individuals with sex chromosome syndromes will be recruited from out-patient clinics Controls will be recruited from the general population|
|Publications *||Not Provided|
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
|Completion Date||January 2016|
|Primary Completion Date||October 2015 (Final data collection date for primary outcome measure)|
Controls should fore fill the criteria below
|Ages||18 Years to 80 Years (Adult, Senior)|
|Accepts Healthy Volunteers||Yes|
|Contacts||Contact information is only displayed when the study is recruiting subjects|
|Listed Location Countries||Denmark|
|Removed Location Countries|
|Other Study ID Numbers||19668|
|Has Data Monitoring Committee||No|
|U.S. FDA-regulated Product||Not Provided|
|IPD Sharing Statement||Not Provided|
|Responsible Party||University of Aarhus|
|Study Sponsor||University of Aarhus|
|PRS Account||University of Aarhus|
|Verification Date||June 2015|